These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 24065837)

  • 21. Changing strategies for hepatitis C testing.
    Teo CG
    Antivir Ther; 2012; 17(7 Pt B):1391-5. PubMed ID: 23322655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response.
    Tedder RS; Tuke P; Wallis N; Wright M; Nicholson L; Grant PR
    J Viral Hepat; 2013 Jan; 20(1):65-71. PubMed ID: 23231086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals.
    Klein MB; Rollet KC; Hull M; Cooper C; Walmsley S; Conway B; Pick N;
    Antivir Ther; 2013; 18(5):717-21. PubMed ID: 23211632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.
    Jenkins ET; Jensen DM
    Infect Dis Clin North Am; 2012 Dec; 26(4):879-91. PubMed ID: 23083821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance evaluation of the Artus hepatitis C virus QS-RGQ assay.
    Paba P; Fabeni L; Perno CF; Ciotti M
    J Virol Methods; 2012 Jan; 179(1):77-80. PubMed ID: 22001273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.
    Shah N; Pierce T; Kowdley KV
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1107-21. PubMed ID: 23735127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C; Jesudian A; Zeuzem S; Jacobson I
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
    Vachon ML; Dieterich DT
    Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
    Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
    Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.
    Harrington PR; Zeng W; Naeger LK
    Hepatology; 2012 Apr; 55(4):1048-57. PubMed ID: 22095516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
    Silva MO; Treitel M; Graham DJ; Curry S; Frontera MJ; McMonagle P; Gupta S; Hughes E; Chase R; Lahser F; Barnard RJ; Howe AY; Howe JA
    J Hepatol; 2013 Jul; 59(1):31-7. PubMed ID: 23454058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of HCV RNA monitoring in the era of new potent therapies.
    Wiesmann F; Braun P
    Expert Rev Anti Infect Ther; 2016 Sep; 14(9):837-44. PubMed ID: 27424603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and Management of Hepatitis C Infection in Primary Care Settings.
    Guss D; Sherigar J; Rosen P; Mohanty SR
    J Gen Intern Med; 2018 Apr; 33(4):551-557. PubMed ID: 29352420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study).
    Calvaruso V; Bronte F; Ferraro D; Reina G; Conte E; Rini F; Magro B; Petta S; Di Marco V; Craxì A
    Liver Int; 2019 Dec; 39(12):2240-2243. PubMed ID: 31502755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus infection in children in the era of direct-acting antiviral.
    Pawlowska M; Sobolewska-Pilarczyk M; Domagalski K
    World J Gastroenterol; 2018 Jun; 24(24):2555-2566. PubMed ID: 29962813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus infection in maintenance hemodialysis patients: recommendations for diagnostics and treatment.
    Dzekova-Vidimliski P; Sikole A
    Int J Artif Organs; 2017 Feb; 39(12):590-595. PubMed ID: 28165585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of acute HCV infection in the era of direct-acting antiviral therapy.
    Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV
    Nat Rev Gastroenterol Hepatol; 2018 Jul; 15(7):412-424. PubMed ID: 29773899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.